Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role and benefits of infectious diseases specialists in the COVID-19 pandemic: Multilevel analysis of care provision in German hospitals using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) cohort.
Tscharntke LT, Jung N, Hanses F, Koll CEM, Pilgram L, Rieg S, Borgmann S, de Miranda SMN, Scherer M, Spinner CD, Rüthrich M, Vehreschild MJGT, von Bergwelt-Baildon M, Wille K, Merle U, Hower M, Rothfuss K, Nadalin S, Klinker H, Fürst J, Greiffendorf I, Raichle C, Friedrichs A, Rauschning D, de With K, Eberwein L, Riedel C, Milovanovic M, Worm M, Schultheis B, Schubert J, Bota M, Beutel G, Glück T, Schmid M, Wintermantel T, Peetz H, Steiner S, Ribel E, Schäfer H, Vehreschild JJ, Stecher M; LEOSS Study Group. Tscharntke LT, et al. Among authors: klinker h. Infection. 2024 Aug 16. doi: 10.1007/s15010-024-02362-2. Online ahead of print. Infection. 2024. PMID: 39150640
[Development and validation of potential structure indicators for clinical infectious disease (ID) care in German hospitals during the COVID-19 pandemic].
Tscharntke L, Stecher M, Classen AY, Jung N, Eberwein L, Friedrichs A, Klinker H, Schons MJ, Spinner CD, J G T Vehreschild M, de With K, Vehreschild JJ. Tscharntke L, et al. Among authors: klinker h. Z Evid Fortbild Qual Gesundhwes. 2023 Feb;176:12-21. doi: 10.1016/j.zefq.2022.11.005. Epub 2023 Feb 6. Z Evid Fortbild Qual Gesundhwes. 2023. PMID: 36754716 Free PMC article. Review. German.
Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study.
Weidlich S, Boesecke C, Schneider J, Klinker HHF, Zink A, Balogh A, Wolf E, Bidner H, Spinner CD; DUALIS study team. Weidlich S, et al. Among authors: klinker hhf. J Antimicrob Chemother. 2020 Oct 1;75(10):3082-3084. doi: 10.1093/jac/dkaa234. J Antimicrob Chemother. 2020. PMID: 32634214 Free PMC article. No abstract available.
Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection-A Case Series of Five Patients With One Virologic Failure After Development of Two-Class Resistance.
Gerstenberg J, Klinker H, Baier M, von Braun A, Seybold U, Helbig C, Däumer M, Korn K, Stephan C, Schleenvoigt BT. Gerstenberg J, et al. Among authors: klinker h. Open Forum Infect Dis. 2024 Aug 23;11(9):ofae480. doi: 10.1093/ofid/ofae480. eCollection 2024 Sep. Open Forum Infect Dis. 2024. PMID: 39286033 Free PMC article.
Addendum „Antivirale Therapie der chronischen Hepatitis-D-Virusinfektion“ zur S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS).
Sandmann L, Berg T, Deterding K, Fischer N, Hinrichsen H, Petersen J, Tacke F, Cornberg M; Collaborators. Sandmann L, et al. Z Gastroenterol. 2023 Dec;61(12):1635-1653. doi: 10.1055/a-2181-3046. Epub 2023 Dec 11. Z Gastroenterol. 2023. PMID: 38081179 Free article. German. No abstract available.
Antiviral Therapy of Chronic Hepatitis D Virus Infection - Addendum to the S3 Guideline "Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection" of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS).
Sandmann L, Berg T, Deterding K, Fischer N, Hinrichsen H, Petersen J, Tacke F, Cornberg M; Collaborators. Sandmann L, et al. Z Gastroenterol. 2023 Dec;61(12):e715-e732. doi: 10.1055/a-2181-3345. Epub 2023 Dec 11. Z Gastroenterol. 2023. PMID: 38081178 No abstract available.
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F, Stein K, Heyne R, Petersen J, Buggisch P, Berg C, Zeuzem S, Stallmach A, Sprinzl M, Schott E, Pathil-Warth A, von Arnim U, Keitel V, Lohmeyer J, Simon KG, Trautwein C, Trein A, Hüppe D, Cornberg M, Lammert F, Ingiliz P, Zachoval R, Hinrichsen H, Zipprich A, Klinker H, Schulze Zur Wiesch J, Schmiedeknecht A, Brosteanu O, Berg T. van Bömmel F, et al. Among authors: klinker h. J Hepatol. 2023 May;78(5):926-936. doi: 10.1016/j.jhep.2022.12.018. Epub 2023 Mar 28. J Hepatol. 2023. PMID: 37062574 Free article. Clinical Trial.
Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib.
Zimmermann S, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Gesierich A, Schilling B, Kalogirou C, Goebeler ME, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O. Zimmermann S, et al. Among authors: klinker h. J Pharm Biomed Anal. 2023 May 10;228:115311. doi: 10.1016/j.jpba.2023.115311. Epub 2023 Feb 23. J Pharm Biomed Anal. 2023. PMID: 36841066
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients.
Gerner B, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Zimmermann S, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O. Gerner B, et al. Among authors: klinker h. Pharmaceutics. 2022 Nov 22;14(12):2556. doi: 10.3390/pharmaceutics14122556. Pharmaceutics. 2022. PMID: 36559050 Free PMC article.
222 results